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ORIGINAL ARTICLE VIROLOGYFrequent detection of high human papillomavirus DNA loads in oral
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1) Virology Laboratory, Department of Molecular Medicine and 2) Department of Oral and Maxillofacial Sciences, Sapienza University, Rome, ItalyAbstractHuman papillomavirus (HPV) is estimated to be the cause of 40–-80% of the squamous cell carcinoma of the oropharynx but only of a small
fraction of the oral cavity cancers. The prevalence of oral HPV infection has significantly increased in the last decade, raising concerns about
the role of HPV in progression of oral potentially malignant disorders (OPMD) toward squamous cell carcinomas. We sought to study HPV
infection in patients with oral lesions, and in control individuals, using non-invasive and site-specific oral brushing and sensitive molecular
methods. HPV DNA positivity and viral loads were evaluated in relation to patient data and clinical diagnosis. We enrolled 116 individuals
attending Dental Clinics: 62 patients with benign oral lesions (e.g. fibromas, papillomatosis, ulcers) or OPMD (e.g. lichen, leukoplakia) and
54 controls. Oral cells were collected with Cytobrush and HPV-DNA was detected with quantitative real-time PCR for the more
common high-risk (HR) and low-risk (LR) genotypes. HPV detection rate, percentage of HR HPVs and HPV-DNA loads (namely HPV16
and in particular, HPV18) were significantly higher in patients than in controls. Lichen planus cases had the highest HPV-positive rate
(75.0%), hairy leukoplakia the lowest (33.3%). This study detected unexpectedly high rates of HPV infection in cells of the oral mucosa.
The elevated HR HPV loads found in OPMD suggest the effectiveness of quantitative PCR in testing oral lesions. Prospective studies are
needed to establish whether elevated viral loads represent a clinically useful marker of the risk of malignant progression.
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E-mail: guido.antonelli@uniroma1.itIntroductionOral cancer is one of the more common cancers worldwide;
early detection of precancerous lesions remains a challenge to
clinicians [1,2]. Although most oral lesions are benign, many
have an appearance that may confound them with oral poten-
tially malignant disorders (OPMD) [1,2]. One of the mostClinical Microbiology and Infection © 2015 European Society of Ccommon oral lesions is squamous papilloma, an exophytic,
pedunculated and usually solitary lesion with small white or red
finger-like projections on the surface [1]. Of the oral cavity
lesions, leukoplakia, defined as ‘a white plaque of questionable
risk having excluded (other) known diseases or disorders that
carry no increased risk for cancer’ [1,2], is considered an
OPMD whereas it is still debated whether lichen planus, a
chronic immuno-inflammatory condition, has potential for
malignant transformation [1–3]. Although the risk of progres-
sion of a single OPMD is low [1–3], the cellular changes and the
associated risk factors leading from epithelial atypia to oral
cancer are not well defined [2–4]. Hence, there is a need to
differentiate and closely monitor those oral lesions at higher
risk of developing cancer [1,2].Clin Microbiol Infect 2016; 22: 95.e9–95.e15
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95.e10 Clinical Microbiology and Infection, Volume 22 Number 1, January 2016 CMIA variable fraction (5–25%) of oral cavity cancer cases is
deemed to be associated with human papillomavirus (HPV)
[5,6]; however, it is not yet clear whether HPV infection acts as
a driving force or as a cofactor in oral carcinogenesis. HPVs are
small double-stranded DNA viruses that infect epithelial tissues
[7]. Mucosal HPV genotypes are classified into low-risk (LR)
types that cause only benign lesions and high-risk (HR) types
associated with anogenital cancers [7,8]. HPV has been recog-
nized to be also the cause of 40–80% of head and neck squa-
mous cell carcinomas, mostly tonsil and base of the tongue
cancers, whose incidence has significantly increased in the last
decade [9]. Importantly, an apparent increase in oral HPV
prevalence was observed in the general population [10–13],
raising concerns about HPV infection and oral cancer risk. In
their recent review [12], Chung et al. noted that the pooled
prevalence of oral HPV infection in healthy individuals between
1997 and 2009 was reported to be 4.5% whereas in a cross-
sectional study conducted between 2009 and 2010, oral HPV
prevalence increased to 6.9% in the general US population
(5579 men and women, aged 14–69 years). More specifically,
oral HPV was prevalent in 32% and 16% of human immuno-
deficiency virus-positive patients and human immunodeficiency
virus-negative patients, respectively, all presenting with oral
lesions [13]. Given recent global trends of HPV oral infection,
the burden of HPV-associated oral cancers is expected to be
higher in the next decades.
Oral HPV infection often occurs with no initial signs or
symptoms of infection, frequently in the absence of clear risk
factors, so that infected individuals are unaware of the infection
for a long time. Undoubtedly, many aspects of oral HPV
infection remain to be clarified, including modes of acquisition,
risk factors, median time to clearance, prevalence of specific
genotypes, clinical relevance of high viral loads, and the different
outcomes of lesions in relation to the risk of developing oral
cancer. In fact, published reports show a marked heterogeneity
in patient population, collection methodology, detection tech-
nique, diagnostic criteria, anatomical location and selection of
control groups [6].
Studying HPV infection and eventually the specific genotype
and viral load, in OPMD and other oral lesions, would help in
elucidating the role of HPV in oral carcinogenesis and could
help to guide future strategies for prevention. To that aim, non-
invasive but site-specific methods of collecting oral cells from
the lesions should be used. Because of its ease of sampling, a
brush biopsy performed with Cytobrush is an adequate tech-
nique for diagnostic cytology smears [4,14] to obtain full
transepithelial cell samples that are also suitable to be tested for
HPV DNA [4]. In view of these considerations and to gain new
insights into HPV oral infection, this study assessed the reli-
ability of HPV testing by sensitive and quantitative molecularClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectmethods in cells collected by Cytobrush from patients with
different types of oral lesions, and from control individuals. In
addition, HPV DNA copy numbers were evaluated in positive
samples to ascertain whether viral loads were related to HPV
risk group, patients’ characteristics or clinical diagnosis.Materials and MethodsStudy population
This study was conducted on 116 individuals (62 cases and 54
controls) consecutively enrolled at the Umberto I Dental Clinic
in Rome during the period January 2013 to October 2014.
Before enrolment, all patients were informed about the pro-
cedure and signed an informed consent form. Exclusion criteria
were unacceptable oral hygiene because poor oral health is a
recognized independent risk factor of oral HPV infection [15].
Individuals enrolled in the study as patients had benign oral
lesions (e.g. fibromas, oral traumatic ulcerative lesions), sus-
pected HPV lesions (e.g. papillomatosis) or OPMD (e.g. leu-
koplakia, lichen planus), whereas the control group was
selected from people attending the Dental Clinic for dental
conditions without clinically evident lesions in the oral mucosa.
Patient data on other localized or systemic diseases and risk
factors, e.g. smoking, were recorded.
A brush biopsy was performed applying a Cytobrush (GPS
Medical, Bergamo, Italy) with a light pressure and rotating on
lesions, to collect a large number of transepithelial cells [14];
brushing was performed inside the whole oral cavity for the
control group. The brushing samples were then suspended in
1 ml phosphate-buffered saline and immediately sent to the
Virology Laboratory for analysis.
HPV detection
Oral brushings were centrifuged at low speed; the cell pellets
then underwent DNA extraction using a QIAamp Blood kit
(Qiagen, Hilden, Germany). Amplification of a 400-bp fragment
of the human leukocyte antigen (HLA) was initially used to
assess the quality of the target DNA, following procedures
routinely adopted in the Virology Laboratory for cervical HPV
detection and previously described [16]. However, several oral
brushes were negative for HLA gene amplification probably
because of fragmented DNA [17]. They were therefore un-
suitable for amplification with the consensus primer MY09/11
widely used in anogenital HPV detection also in our Laboratory
[16]. To overcome this problem, we used HPV type-specific
quantitative real-time PCR (qPCR) fluorogenic assays, imple-
mented in a previous study [18], that provide a greater
analytical sensitivity without requiring intact genomic DNA. To
avoid false-negative results, all samples were tested for theious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 22, 95.e9–95.e15
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in a
semi-quantitative way. Accordingly, HPV type-specific primers
and TaqMan probes for the more common low-risk (HPV6, 11)
and high-risk (16, 18, 31, 33, 53, 58) HPV genotypes were used
and copy numbers were measured in samples by means of HPV
plasmid external curves [18]. Total DNA concentration was
calculated by reading optical density at 260 nm and viral load
was determined as HPV copy number per nanogram of total
DNA in each sample [18].
Statistical analysis
The chi-square test (two-sided) was used in the statistical
analysis of different groups. The non-parametric test for pair-
wise comparisons, Mann–Whitney U test, was used for ana-
lysing viral load values of cases versus controls of LR versus HR
and of HPV16 versus HPV18 infections. Statistical tests were
considered significant if the p value was 0.05. Data analysis
was carried out with SPSS v.17.0 for Windows.ResultsHPV detection
A total of 116 oral samples were obtained from the Dental
Clinic (Table 1): 62 were from patients with oral lesions and 54
from controls. Patients’ mean age (53.8 years) was higher,
though not at a statistically significant level, than that in the
control group (40.8 years); attending the clinics for dental
conditions is probably more frequent at a younger age.
Total purified DNA concentration median value was 6.9 mg/
L (range 1.0–18.9 mg/L); DNA in samples collected from pa-
tients was 6.1 mg/L (range 1.0–14.1 mg/L) and from controls
was 6.3 mg/L (range 1.2–18.9 mg/L) and the difference was not
statistically significant (p > 0.05). All collected samples were
positive for semi-quantitative amplification of the GAPDH gene,TABLE 1. Human papillomavirus (HPV) genotype and viral loads in
Casesa
(n = 62)
Mean age, years (range) 53.8 (17–83)
Gender, male (%) 29 (46.8%)
Any HPV (%)c 33/62 (53.2%)
HPV genotypesd 6 [3],11 [1], 16 [18],18 [6],31 [1],33 [2],53
HR HPV (%)c 29/33 (87.9%)
LR HPV (%)c 4/33 (12.1%)
HR HPV viral load, median (range)e 2 × 104 (4.3 × 102 to 1.3 × 107)
LR HPV viral load, median (range)e 2.8 × 103 (4.3 × 101-4.4 × 103)
aPatients attending the Dental clinic with oral mucosa lesions.
bIndividuals attending the Dental clinic for dental conditions.
cQuantitative PCR was performed for the high-risk (HR) types: HPV16, 18, 31, 33, 53, 58 a
attributed to HR/LR HPV from the total HPV-positive cases in the group.
dValues in square brackets are the number of detections for each genotype.
eViral loads of HR HPV genotypes are median values (range) of determinations expressed as
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology andso that apparently, all results were interpretable with respect to
the cellular control.
Overall, 52/116 samples (44.8%) were positive for one of the
HPV genotypes tested in the study; no multiple infection was
found either in cases or in controls. The HPV positivity rate was
higher in the case group (33/62, 53.2%) than in the control
group (19/54, 34.5%) at a borderline statistically significant level
(p 0.042) with a significantly higher (p 0.027) percentage of HR
HPVs in samples from the cases (29/33, 87.9%) than in the
control samples (12/19, 63.2%). HPV16 was the most
frequently detected HPV genotype in both groups; HPV18, the
second most common in cervical cancer, ranked second in
patient infections. In the control group, which had more
low-risk infections than the patients group, the low-risk HPV6
was the second most common genotype detected (Table 1).
Viral loads
In the light of the above results, we sought to evaluate HPV oral
infections comparing cases and controls, focusing on type-
specific HPV-DNA load in samples calculated as HPV-DNA
copy number per nanogram (ng) of total DNA in each sam-
ple. Median values in cases and controls are reported in Table 1.
Interestingly, despite a wide variability, the median number of
HPV-DNA copies in oral samples from cases (median cases
1.9 × 104 copies/ng; range: 4.3 × 101 to 1.3 × 107) was signif-
icantly higher (p 0.000, Mann–Whitney U test) than that from
controls (median controls 1.1 × 102 copies/ng; range: 6.5 × 101
to 8.5 × 105) (Fig. 1). Moreover, viral loads of HR HPV from
cases (median cases 2 × 104 copies/ng; range: 4.3 × 102 to
1.3 × 107) were significantly higher (p < 0.0001, Mann–
Whitney U test) than those from controls (median con-
trols = 1 × 103 copies/ng; range: 5.2 × 101 to 8.5 × 105)
(Table 1). In addition, HPV16-positive samples of the patient
group had a significantly higher (p 0.003, Mann–Whitney U
test) median viral load (median cases 1.4 × 104 copies/ng; range:
4.3 × 102 to 6.5 × 106) than that of HPV16-positive controlsoral samples from case and control groups
Controlsb
(n = 54) p
40.8 (23–75) n.s.
28 (51.8%) n.s.
19/54 (34.5%) 0.042
[1],58 [1] 6 [7], 16 [9],18 [1],33 [1],53 [1]
12/19 (63.2%) 0.027
7/19 (36.8%)
1 × 103 (5.2 × 101 to 8.5 × 105) 0.000
4.6 × 102 (6.5 × 101 to 1.7 × 104) n.s.
nd the low-risk (LR) types: HPV6, HPV11. (%): percentages are the number of cases
number of copies/ng input DNA in cases and controls.
Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 22, 95.e9–95.e15
FIG. 1. Median values of type-specific
human papillomavirus (HPV) DNA load.
Results are cumulative data from 62 pa-
tients and 54 controls participating in the
study and are expressed as HPV copy
number (Log) per nanogram of total
DNA in each sample. The non-
parametric Mann–Whitney U test was
used for pairwise comparisons of viral
load values between the two groups.
95.e12 Clinical Microbiology and Infection, Volume 22 Number 1, January 2016 CMI(median controls 9.1 × 102 copies/ng; range: 5.2 × 101 to
8.5 × 105). Of note, HPV18-infected only one individual in the
control group whereas HPV18-positive patients had the highest
viral loads in lesions (Fig. 2), significantly higher than HPV16
(median DNA copies/ng: HPV18 1.8 × 106 versus HPV16
1.4 × 104; p < 0.0001, Mann–Whitney U test).
Patient characteristics and lesions
In the case group, we evaluated HPV results and patient risk
factors, clinical diagnosis and affected sites in the oral cavity
(Table 2). There was no significant difference between HPV-
negative, HR or LR HPV-positive patients in terms of mean
age, gender, smoking habit or underlying clinical conditions
(Table 2).
The highest HPV infection rates were in patients clinically
diagnosed with lichen planus (HPV-positive 9/12 cases, 75.0%),
followed by papillomatosis (HPV-positive 14/24, 58.3%), other
types of oral lesions, i.e. traumatic ulcers, fibromas, a burning
sensation of the oral mucosa (HPV-positive 7/17, 41.2%), and
leukoplakia (HPV-positive 3/9, 33.3%) (Table 2). No specific
HPV genotype or differences in viral loads were associated with
a particular clinical diagnosis or affected site.DiscussionIn normal oral mucosa, reported HPV DNA positivity rates
vary considerably among different population groups, but alsoClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectdepend on which oral sample is collected [19–24] as oral rinse
and gargle, saliva, oral swabs, oral brushings and biopsies have
different oral mucosa cell contents. Oral HPV infection was
estimated to be around 7% in US adults [24,25] but ranges from
4.4% when testing only oral rinse [12] to 12.3% when testing
oral rinse and oral swabs [22]. In oral cells taken with Cyto-
brush from Finnish women of reproductive age [26], the rate of
HPV positivity was 18–24%, whereas in bioptic samples of
normal oral mucosa, HPV positivity was 40% [23].
In this study, to test for HPV infection, a microbrush of the
type used in the collection of cervical samples (Cytobrush) was
used to collect samples from oral lesions. Several studies have
suggested that the Cytobrush collection method permits non-
invasive evaluation of potentially malignant lesions by detect-
ing atypia in cells from brush biopsies of lesional material [4,14],
which are also suitable for HPV DNA testing [4,20,21]. Using
Cytobrush allows the oral mucosa to be tested reaching the
non-keratinized strata of the epithelium [14], which is not
achieved in oral rinse samples. As a result of the absence of
patient discomfort that limits collection of bioptic samples,
general dentists and stomatologists could use this technique,
which is well-accepted by the patient, also in a screening
context, in the absence of overt lesions. In this study, we ob-
tained cells in a comparable amount in both groups, lightly
brushing the whole oral cavity in control individuals and directly
on the site of clinically evident lesions in the patient group. In
patients, brushing the lesions can maximize the chance to
detect HPV DNA, which is consistent with the fact that positiveious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 22, 95.e9–95.e15
FIG. 2. Median values of type-specific
human papillomavirus (HPV) DNA load.
Results are cumulative data from HPV16
(n = 18) and HPV18 (n = 9) samples from
patients participating in the study and are
expressed as HPV copy number (Log)
per nanogram of total DNA in each
sample. The non-parametric Mann–
Whitney U test was used for pairwise
comparisons of viral load values between
HPV16 and HPV18.
CMI Pierangeli et al. High human papillomavirus DNA loads in oral lesions 95.e13HPV detection on the oral mucosa seems to be associated with
lesions in particular anatomical sites [27].
To overcome technical difficulties in HPV detection, we
performed type-specific qPCR instead of the nested PCRTABLE 2. Patient demographic and clinical data stratified
according to human papillomavirus (HPV) results
Patient data
HPV-positive
(n = 33)
HPV-negative
(n = 29)
Mean age, years (range) 52.6 (17–83) 55.1 (21–79)
Male 13 16
Female 20 13
Risk factorsa
None 13/29 8/27
Smoking 5/29 8/27
Systemic conditions 12/29 9/27
Non-systemic conditions 5/29 4/27
Clinical diagnosis
Lichen planus 9 (75.0%) HPV: 6 [1],16 [6],
18 [1],31 [1]
3 (25.0%)
Papillomatosis 14 (58.3%) HPV: 6 [1],16 [6],
18 [3],33 [2], 53 [1], 58 [1]
10 (41.7%)
Leukoplakia 3 (33.3%) HPV: 16 [2],18 [1] 6 (66.7%)
Other lesionsb 7 (41.2%) HPV:6 [1],11 [1],
16 [4] ],18 [1]
10 (58.8%)
Site of the lesion
Cheek mucosa 3 (30.0%) HPV:6 [1],16 [1],18 [1] 7 (70.0%)
Hard palate 5 (62.5%) HPV: 16 [2],18 [3] 3 (37.5%)
Soft palate 4 (57.1%) HPV:16 [1],31 [1],
33 [1],58 [1]
3 (42.9%)
Oral cavity 2 (40.0%) HPV:16 [2] 3 (60.0%)
Floor of the mouth 2 (50.0%) HPV: 11 [1],16 [1] 2 (50.0%)
Lingual margins and belly 3 (60.0%) HPV: 6 [1],16 [1],18 [1] 2 (40.0%)
Back of the tongue 10 (58.8%) HPV:6 [2],16 [7],53 [1] 7 (41.2%)
Periodontal mucosa 3 (75.0%) HPV:16 [1],18 [1],33 [1] 1 (25.0%)
Retromolar trine 1 (50.0%) HPV: 16 [1] 1 (50.0%)
aRisk factors are known for 56 patients out of 62; no significant difference was
found between HPV-positive and HPV-negative patients.
bOther lesions of the oral cavity include: traumatic ulcers, fibromas, and a burning
sensation of the oral mucosa.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology andtechniques used in most previous works [19–21,26]. Our PCR
assays are specifically designed to yield small amplicons, as
appropriate for possibly degraded DNA [17]. Besides, qPCR
also has the advantage of being rapid, quantitative, and less
prone to contamination. An obvious feature of this method is
that, while adding information on the specific HPV genotype,
testing all mucosal HPVs in a sample is not routinely feasible. In
this study we detected the HR HPV genotypes associated with
the higher percentage of cervical cancer cases (16, 18, 31, 33)
and the other HPV genotypes (the HR HPVs 53 and 58, and the
LR HPVs 6 and 11) more frequently detected in Rome ac-
cording to our previous paper [17]. Testing a limited number of
genotypes can also explain the fact that no multiple infections
were detected in this study. In other studies related to oral
cavity, HPV multiple infections were in the range of 5–13%
[14,23,26], rates apparently lower than in cervical infections.
In this study, the control group’s rate of HPV positivity
(34.5%) was much higher than in previous Italian studies [20,28]
but comparable to recent papers [23,29], so in keeping with the
worldwide increase in oral HPV prevalence [12].
To our knowledge, this study is the first to quantify in
OPMD and other oral lesions, several HR HPV genotypes other
than HPV16, and the LR genotypes HPV6 and 11. Previous in-
vestigations either quantified only the overall (i.e. non-type-
specific) viral load, or focused on HPV16 so that little is
known on the other genotypes. Only one recent study [25]
comprehensively quantified HR HPV infections in the oral
rinse from a US general population cohort, but did not quantifyInfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 22, 95.e9–95.e15
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smoking were associated with a high oral load of HR HPV types
among individuals with a prevalent infection. These results are
not directly comparable with ours, given the differences in the
study group, in the sampling techniques, in the number of HR
genotypes tested and in the expression of viral load results. The
last issue is highly debated in the field because different tech-
niques are used for expressing viral load with respect to the
input DNA in the sample and it is difficult to compare different
studies. Anyway, interesting differences emerged from our
analysis of viral load results: the cases had significantly higher
median loads of HR HPV with respect to LR, and of HPV16 with
respect to controls, all findings consistent with the reported
predominant role of HPV16 in OSCC [30,31]. Nonetheless,
our data showed that HPV18 might also play an important role
in oral infections with elevated viral loads that could cause a risk
of persistence. It has been shown that HPV16 cervical infections
(but not those of other HPV genotypes) with high DNA loads
are at greater risk of clinical progression [32]. Oral HPV16 load
was significantly associated with the time to clearance of oral
infections in a recent paper [33]; in this respect, HPV18 oral
infections were not addressed.
Comparing our results of HPV detection in the different oral
lesions, we noted a very high positivity in lesions clinically
diagnosed as lichen planus (75%) whereas the other lesions had
comparable rates of HPV positivity with respect to previous
reports [20,30,31]. In particular, previous Italian studies
detected HPV DNA by nested PCR performed in exfoliated
mucosal cells in 17–22% of leukoplakia cases and 20–25% of
lichen planus [21,28]. In other recent studies and meta-analyses,
HPV detection rates in oral lichen planus range from 10% to
33% [30,31,34,35]; we cannot presently explain this discrepancy
with the high HPV detection rates in lichen planus in this study.
Lichen planus is a chronic inflammatory autoimmune disease [3]
and the frequent ulceration makes this lesion more susceptible
to HPV infection. HPV oncogenes in turn may help proliferating
epithelial cells to escape apoptosis [7,34,35] but the HPV
contribution to the risk of oral cancer is still uncertain. Pro-
spective studies correlating HPV type-specific detection with
histology and other host cell biomarkers are needed to clarify
this issue.
In conclusion, this study implemented a non-invasive sample
collection method with a sensitive and quantitative molecular
method, detecting high rates of oral HPV-DNA. The notion of
oral HPV infection as a not uncommon condition in normal oral
mucosa poses potential for vaccine-based prevention, consid-
ering that the vaccine genotype HPV16 was the most frequently
detected. It remains to be clarified whether low viral loads in
the absence of a clinically evident lesion could be indicative of
transient infections. Conversely, HPV infections at elevated viralClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectloads, such those we found in HPV16 and HPV18, could be
associated with an increased risk of persistence and progres-
sion, to be tested in prospective studies.
Considering the rising incidence of oral cancer, these findings
could be relevant to dentists and stomatologists to enhance
their knowledge in this area and for clinical patient
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